Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials

OBJECTIVE: Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor. DESIGN: Pooled post hoc analysis. SETTING: Six phase 3 or phase 4 placebo‐controlled randomised trials with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Kusha A., Brackin, Taylor, Schwartz, Gregory G., Steg, Philippe Gabriel, Szarek, Michael, Manvelian, Garen, Pordy, Robert, Fazio, Sergio, Geba, Gregory P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501297/
https://www.ncbi.nlm.nih.gov/pubmed/37458138
http://dx.doi.org/10.1002/cam4.6310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501297/
https://www.ncbi.nlm.nih.gov/pubmed/37458138
http://dx.doi.org/10.1002/cam4.6310

Ejemplares similares